Metagenomi Therapeutics, Inc. (MGX)
NASDAQ: MGX · Real-Time Price · USD
0.6138
-0.0180 (-2.85%)
At close: Nov 19, 2026, 4:00 PM EST
0.6260
+0.0122 (1.99%)
After-hours: Nov 19, 2026, 7:45 PM EST
Metagenomi Therapeutics Revenue
Metagenomi Therapeutics had revenue of $2.18M in the quarter ending September 30, 2026, a decrease of -74.78%. This brings the company's total for the last twelve months to $7.09M, down -77.08% year-over-year. In the year 2025, Metagenomi Therapeutics had annual revenue of $25.21M, down -51.79%. That makes Metagenomi Therapeutics the 38,770th largest company in the world by revenue and 5,100th in the United States.
Revenue (ttm)
$7.09M
Revenue Growth
-77.08%
P/S Ratio
3.26
Revenue / Employee
$66,224
Employees
107
Market Cap
23.21M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 25.21M | -27.09M | -51.79% |
| Dec 31, 2024 | 52.30M | 7.54M | 16.84% |
| Dec 31, 2023 | 44.76M | 27.56M | 160.21% |
| Dec 31, 2022 | 17.20M | 16.96M | 6,978.19% |
| Dec 31, 2021 | 243.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Pelthos Therapeutics | 51.29M |
| Evaxion | 7.49M |
| BeyondSpring | 1.88M |
| ABVC BioPharma | 797.92K |
| CervoMed | 8.73K |
MGX News
- 1 day ago - Metagenomi Therapeutics Transcript: Jefferies Global Healthcare Conference - Transcripts
- 8 days ago - Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference in London - GlobeNewsWire
- 9 days ago - Metagenomi announces FDA clearance of IND application for MGX-001 - TheFly
- 9 days ago - Metagenomi Therapeutics Announces FDA Clearance of Investigational New Drug Application for MGX-001 and Reports Third Quarter 2026 Financial Results - GlobeNewsWire
- 9 days ago - Metagenomi Therapeutics Earnings release: Q3 2026 - Filings
- 9 days ago - Metagenomi Therapeutics Quarterly report: Q3 2026 - Filings
- 15 days ago - Metagenomi Therapeutics to Present Preclinical Data Supporting MGX-001, a Potential One-Time Therapy for Hemophilia A, in Oral Presentation at 68th American Society of Hematology Annual Meeting - GlobeNewsWire
- 4 weeks ago - Metagenomi Therapeutics Transcript: Chardan's 10th Annual Healthcare Conference - Transcripts